The global hemophilia treatment market is poised for remarkable growth, with estimates projecting an increase from USD 12.1 billion in 2024 to an impressive USD 18.7 billion by 2034. This substantial ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor ... for the blood-clotting disorder ...

Injection-site reactions ... release that results for another arm of the BASIS trial in patients with clotting factor inhibitors are expected in 2025. M. Alexander Otto is a physician assistant ...

Elocta was associated with better bleed control and fewer injections for hemophilia A patients in a real-world European study ...

The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...

Haemophilia is a rare bleeding disorder affecting less than 0.01 per cent of Malaysians, requiring daily medical ...

The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened ...

Hympavzi is a new type of drug that, rather than replacing a clotting factor, works by reducing ... The most common side effects of Hympavzi are injection site reactions, headache and itching ...

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII ... effects of Hympavzi are injection site reactions, headache ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

The once-weekly injection prevents or reduces the ... who usually require regular infusions of proteins called factor IX that ...